Latest

19:50
【Innogen-B (02591.HK): Two Contract Manufacturing Sites for Isupaglutide α Injection Obtain PIC/S GMP Certificates】NewTimeSpace News: Guangzhou Innogen Pharmaceutical Group Co., Limited (02591.HK) announced that two contract manufacturing sites in China for Isupaglutide α Injection have passed compliance inspection conducted by Brazil’s ANVISA in accordance with PIC/S GMP standards and obtained relevant GMP certificates, confirming that the production and quality management systems comply with PIC/S GMP requirements.
Tag： INNOGEN-B02591.HKGMP
19:45
【CSPC PHARMA(01093.HK): Phase Ib/II Clinical Trial of SYS6090 Injection for Colorectal Cancer Initiated at First Study Centre in China】NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that the Phase Ib/II clinical trial (SYS6090-008) evaluating the combination therapy of SYS6090 Injection for colorectal cancer developed by the Group has officially been initiated at the first study centre in China. The product is a recombinant fully human anti-PD-1 fusion protein fused with IL-15, classified as Class 1 therapeutic biological product.
Tag： CSPC PHARMA01093.HKClinical Trial
19:01
【Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies】NewTimeSpace News: Ascletis Pharma Inc. (01672.HK) announced that once-daily oral small-molecule GLP-1 ASC30 has obtained FDA clearance to initiate global Phase III clinical studies. Two pivotal trials will be conducted in the United States, Europe and Canada, enrolling approximately 4,600 obese or overweight subjects. Meanwhile, the Company disclosed first-in-class oral small-molecule GLP-1/GIP/amylin triple-target fixed-dose combination (FDC) achieved up to 15.2% weight loss in non-human primates, representing a relative improvement of 120% compared with the dual-target formulation.
Tag： ASCLETIS-B01672.HKClinical Trial
18:43
【WUXI APPTEC(02359.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 11.08 billion, YoY increase of 33.7%】NewTimeSpace News: August 03, 2026, WUXI APPTEC(02359.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 28.9 billion, increased by 38.94% YoY。
Tag： WuXi AppTec02359.HKprofit growth
18:41
【SH PHARMA(02607.HK): Omeprazole Sodium Bicarbonate for Oral Suspension (I) Approved for Production】NewTimeSpace News: SH PHARMA (02607.HK) announced that its subsidiary SPH Xinyi has obtained the Drug Registration Certificate for Omeprazole Sodium Bicarbonate for Oral Suspension (I) issued by the National Medical Products Administration, and the drug is approved for production. Each sachet contains 20mg Omeprazole and 1680mg Sodium Bicarbonate. Classified as Class 3 Chemical Drug, it is mainly indicated for short-term treatment of active duodenal ulcer and gastroesophageal reflux disease.
Tag： SH PHARMA02607.HKDrug Registration Certificate
18:26
【LING YUE SER GP(02165.HK): Unsuccessful Tender for Sichuan Land in Public Bidding; Tender Deposit Fully Refunded】NewTimeSpace News: Ling Yue Services Group Limited (02165.HK) announced on 3 August that it failed to win the public bidding for the land use right in Xichang City, Sichuan Province. The tender deposit of RMB8.33 million has been fully refunded without interest and deductions. The Company will continue to search for investment opportunities.
Tag： LING YUE SER GP02165.HKpublic bidding
18:20
【Jinhai Med Tech (02225.HK): Appoints Ma Chengdong as Chief Marketing Officer to Accelerate Foray into Neurosurgical Endoscopy Sector】NewTimeSpace News: Jinhai Medical Technology Limited (02225.HK) announced that Mr. Ma Chengdong has been appointed as the Group’s Chief Marketing Officer, effective 3 August 2026. He will mainly be responsible for product marketing strategies, market access, academic promotion, sales and channel operation of the Group. Graduated from Shanghai Medical University, Mr. Ma boasts over 25 years of experience in marketing and sales management at international medical enterprises including GE Healthcare China and Medtronic China.
Tag： JINHAI MED TECH02225.HKChief Marketing Officer
18:11
【SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement】NewTimeSpace News: SSY Group (02005.HK) announced that all 16 specifications covering 13 varieties tendered by the Group are proposed to be selected in the bidding of the 12th National Centralized Drug Procurement. The products include Blonanserin Tablets, Betahistine Mesilate Tablets, Vitamin B6 Injection, Acipimox Capsules, Doxazosin Mesilate Sustained-release Tablets, Bisoprolol Amlodipine Tablets and other varieties.
Tag： SSY Group02005.HKproposed to be selected
18:06
【XPENG-W(09868.HK): Delivered 38,027 New Vehicles in July, Up 4% YoY; Cumulative Global Deliveries Exceed 1.2 Million Units】NewTimeSpace News: XPeng Inc. (09868.HK) announced on 4 August that it delivered 38,027 vehicles in July, representing a 4% year-on-year increase. Cumulative global deliveries have surpassed 1.2 million units. The global model L03 will be launched in 65 countries and regions. Five new models will be rolled out in Australia in the second half of the year, and the VLA 2.0 intelligent driving system will be launched globally in 2027. Estimated carbon emission reduction exceeds 3.23 million tonnes from January to July.
Tag： XPENG-W09868.HKSmart Driving
17:59
【EuroEyes (01846.HK): Appointment of Rens Laurentius Michaël Schoenmakers as Executive Director】NewTimeSpace News: EuroEyes International Eye Clinic Limited (01846.HK) announced that Mr. Rens Laurentius Michaël Schoenmakers has been appointed as an executive director, effective 3 August 2026. Aged 60, Mr. Schoenmakers possesses over 20 years of senior management experience in medical devices, medtech and healthcare sectors. He currently serves as General Manager for Europe of the Group and Chief Executive Officer of EuroEyes Netherlands Holding B.V.
Tag： EUROEYES01846.HKexecutive director
17:54
【Fusen Pharm (01652.HK): Four Products Proposed to Be Selected in the 12th National Centralized Drug Procurement】NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) announced that four of the Group’s products have been proposed to win the bid in the tender of China’s 12th National Centralized Drug Procurement, namely Nicardipine Injection, Azilsartan Potassium Tablets, Potassium Hydrogen Phosphate Compound Injection and Dydrogesterone Tablets.
Tag： FUSEN PHARM01652.HKproposed to be selected
17:43
【Xiabuxiabu (00520.HK): First-Half Loss Narrowed Significantly】NewTimeSpace News: Xiabuxiabu announced on August 3 that it expects a net loss of approximately RMB29 million to RMB39 million for the six months ended June 30, 2026. The loss represents a narrowing of roughly 51% to 64%, compared with the loss of RMB81 million in the same period last year.
Tag： XIABUXIABU00520.HK
17:35
【CGN Power (01816.HK): Huizhou Unit 2 Ready for Commercial Operation; Number of Operating Units Rises to 31】NewTimeSpace News: CGN POWER (01816.HK) announced that Unit 2 of CGN Huizhou Nuclear Power Co., Limited completed all commissioning works and satisfied the conditions for commercial operation on 3 August 2026. Following the commissioning of Huizhou Unit 2, the number of operating nuclear power units managed by the Company (including joint ventures) increased to 31, and the installed capacity of operating units rose from 34,248 MW to 35,450 MW.
Tag： CGN POWER01816.HKnuclear power
17:31
【JS Global Lifestyle (01691.HK): Expected Net Profit of No Less Than US$12 Million for First Half】NewTimeSpace News: JS Global Lifestyle announced on August 3 that it expects to record a net profit of no less than US$12 million for the six months ended June 30, 2026, swinging from a net loss of approximately US$53.7 million in the same period last year.
Tag： JS Global Lifestyle01691.HK
17:21
【REGENT PACIFIC GROUP (00575.HK): Expected to Swing to Profit in First Half】NewTimeSpace News: REGENT PACIFIC GROUP announced on August 3 that it expects to record a profit of approximately US$500,000 to US$1 million for the six months ended June 30, 2026, swinging from a loss of around US$2.22 million in the same period last year.
Tag： Regent Pacific Group00575.HK
17:14
【JIU RONG HOLD(02358.HK): Supplementary Disclosure of Remaining Mortgaged Assets under Litigation of RMB134 Million, Insufficient to Cover Outstanding Loan Principal】NewTimeSpace News: Jiu Rong Holdings Limited (02358.HK) released a supplementary announcement disclosing details of remaining mortgaged assets involved in litigation. As at 30 June 2025, the aggregate book value of remaining mortgaged assets stood at approximately RMB134 million, including new energy charging station assets worth about RMB40.22 million and accounts receivable from Banco Nacional de Cuba of roughly RMB93.63 million. After offsetting approximately RMB42 million via assignment of claims, the outstanding loan principal amounted to around RMB188 million, and the book value of mortgaged assets is insufficient to cover the residual principal.
Tag： JIU RONG HOLD02358.HKLitigation
17:13
【Sisram Medical Ltd (01696.HK): Expected First-Half Loss of US$900,000 to US$1.4 Million】NewTimeSpace News: Sisram Medical Ltd announced on August 3 that it expects a loss attributable to owners of the company of approximately US$900,000 to US$1.4 million for the six months ended June 30, 2026.
Tag： Sisram Medical Ltd01696.HK
17:08
【APEX ACE HOLDING (06036.HK): Expected Interim Profit of HK$130 Million to HK$140 Million】NewTimeSpace News: APEX ACE HOLDING announced on August 3 that it expects profit attributable to owners of the company for the six months ended June 30, 2026 to range from HK$130 million to HK$140 million.
Tag： APEX ACE HOLDING06036.HK
16:40
【SBP GROUP(01177.HK): HER2 Bispecific ADC TQB2102 Receives Third CDE Breakthrough Therapy Designation for HER2-Low】NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced on August 3 that its HER2 bispecific ADC TQB2102 has received its third Breakthrough Therapy Designation (BTD) from CDE, this time for chemotherapy-naïve HER2-low breast cancer. Clinical data demonstrated an ORR of 53%–58%, with efficacy also observed in patients previously treated with ADCs. Approximately 45%–55% of breast cancer patients in China are HER2-low, where existing treatment options remain limited. The Company is advancing multiple Phase III studies.
Tag： SBP GROUP01177.HKbreakthrough drug
15:52
【Autonomous Driving Concept Stocks Watch | BIDU-SW (09888.HK) strengthens in afternoon trading；The regulatory compliance framework for the robotaxi industry continues to improve】NewTimeSpace News: On August 3, 2026, BIDU-SW (09888.HK) strengthened in afternoon trading. As of 15:28, the stock traded at HK$109.90 intraday, marking a 3.78% increase. The compliance regulatory framework for the robotaxi industry is continuously improved; relevant enterprises have achieved profitable operations and kicked off global expansion.
Tag： BIDU-SW09888.HKAutonomous Driving
Previous1..123124 125126127..483     483 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments